Why Is Onfi So Hard to Find? [Explained for 2026]

You walk up to the pharmacy counter with your Onfi prescription in hand — and you're told it's out of stock. Again. If this scene sounds familiar, you're not alone. Onfi (clobazam), a medication that people with Lennox-Gastaut syndrome (LGS) and other epilepsy types depend on to control their seizures, has become increasingly difficult to find at pharmacies across the United States.

Missing doses of Onfi isn't just inconvenient — for patients who depend on it for seizure control, it can be dangerous. In this article, we'll explain exactly why Onfi is so hard to find in 2026, what's driving the supply problems, and what you can do right now to get your medication.

What Is Onfi and Who Needs It?

Onfi is the brand name for clobazam, a 1,5-benzodiazepine approved by the FDA in October 2011 as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older. LGS is a severe form of childhood-onset epilepsy that causes multiple types of seizures, cognitive impairment, and developmental delays.

Onfi is also prescribed off-label for other forms of refractory epilepsy, Dravet syndrome, and catamenial epilepsy. It comes as 10 mg and 20 mg tablets, a 2.5 mg/mL oral suspension, and as a dissolvable oral film under the brand name Sympazan. Because LGS is a relatively rare condition, the population that depends on Onfi is smaller — but no less in need.

Is There an Onfi Shortage in 2026?

As of 2026, Onfi and generic clobazam continue to face intermittent availability problems. While clobazam isn't always listed as an active shortage on the FDA's official Drug Shortages database, patients across the country continue to report difficulty finding it at their local pharmacies — particularly the oral suspension formulation, which has been the hardest hit.

The problem started around 2019–2020 when generic clobazam became widely available following patent expiration. While this created more supply options in theory, it also created more points of failure. Since then, supply fluctuations have continued, with periodic improvements followed by new disruptions.

Why Is Onfi Hard to Find? 5 Key Reasons

Several factors combine to make Onfi and clobazam harder to access than most medications:

1. Manufacturing disruptions. Generic clobazam has experienced intermittent manufacturing problems since around 2020. Raw material shortages, production delays, and quality control issues at manufacturing facilities have all contributed to gaps in supply. The oral suspension formulation has been particularly vulnerable. When one manufacturer has a problem, others often can't ramp up fast enough to meet demand — creating a ripple effect. For the full shortage update, see our Onfi shortage update for 2026.

2. Small patient population, few manufacturers. Lennox-Gastaut syndrome is a rare condition. Because the overall clobazam patient population is much smaller than blockbuster drugs like blood pressure medications, fewer generic manufacturers choose to produce it. When any one of those manufacturers drops out, the impact is outsized.

3. Controlled substance regulations. Onfi is a Schedule IV controlled substance (C-IV) under DEA regulations. This means manufacturers must obtain a DEA production quota each year, and pharmacies must follow strict ordering, storage, and dispensing rules. These regulations add friction to the supply chain that doesn't exist for non-controlled medications.

4. Pharmacy stocking decisions. Large chain pharmacies stock medications based on local demand and national supply agreements. Because clobazam is a niche drug, some chains don't maintain consistent inventory. Independent pharmacies and specialty pharmacies that serve neurology patients often have more reliable stock.

5. The oral suspension shortage. The 2.5 mg/mL oral suspension, which is especially important for young children and patients who cannot swallow tablets, has been disproportionately affected by supply disruptions. Pediatric LGS patients and their families have faced particular difficulty with this formulation.

Is Cost Also a Barrier?

Cost is another challenge. Brand-name Onfi can cost $745 to over $1,000 for a 30-day supply at retail price. Generic clobazam tablets are far more affordable, typically ranging from $30 to $150 depending on your dose and pharmacy. Discount cards from services like GoodRx and SingleCare can bring generic clobazam as low as $18–$90 for a common prescription (e.g., 60 tablets of 10 mg).

Most commercial insurance plans and Medicare cover generic clobazam, though brand-name Onfi may require prior authorization. If you're uninsured, Lundbeck offers a patient assistance program for eligible patients, and the Epilepsy Foundation maintains resources for medication access.

What Should You Do If You Can't Find Onfi?

If your usual pharmacy is out of stock, here are practical steps to take:

• Call multiple pharmacies. Don't stop at one — call independent pharmacies, specialty pharmacies, and compounding pharmacies in your area.
• Ask about different formulations. If the tablet is unavailable, the suspension or Sympazan oral film may be in stock — or vice versa. Different formulations come from different supply chains.
• Contact your doctor immediately. Never stop Onfi abruptly — this can trigger serious withdrawal seizures or status epilepticus. Your doctor can help bridge your supply or adjust your plan.
• Start refilling early. Don't wait until you're out. As a Schedule IV medication, you may have limited early-fill windows — but knowing in advance gives you time to problem-solve.
• Use medfinder. medfinder is a service that calls pharmacies near you to check which ones have your medication in stock. Instead of spending hours on the phone yourself, medfinder does the calling for you and texts you the results.

Are There Alternatives to Onfi?

If you truly cannot find Onfi and your neurologist agrees that a short-term alternative is appropriate, there are options to discuss. Clonazepam (Klonopin) is the most pharmacologically similar alternative, though it is generally more sedating. Valproate, lamotrigine, and rufinamide (Banzel) are other anti-seizure medications used in LGS management. For a full breakdown, see our guide to alternatives to Onfi. Always consult your neurologist before making any changes to your seizure medication.

The Bottom Line

Onfi is hard to find in 2026 because of a combination of manufacturing vulnerabilities, a small specialty market, controlled substance regulations, and inconsistent pharmacy stocking. The supply situation is unlikely to fully resolve in the near term. The best defense is proactive planning: refill early, know your backup options, and use tools like medfinder to locate stock near you before you run low. And if you're ever running critically low on Onfi, contact your neurologist immediately — never stop this medication suddenly.